Natera, Inc. $NTRA Stock: China Universal Asset Management Co. Ltd. Lowers Position

China Universal Asset Management Co. Ltd. trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 67.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,165 shares of the medical research company’s stock after selling 2,435 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Natera were worth $483,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of NTRA. BlackRock Inc. acquired a new position in shares of Natera in the 2nd quarter valued at about $2,962,770,000. K.J. Harrison & Partners Inc purchased a new stake in shares of Natera in the second quarter worth approximately $5,117,000. Abbot Financial Management Inc. acquired a new stake in shares of Natera during the second quarter worth approximately $1,537,000. Eagle Health Investments LP acquired a new stake in shares of Natera during the second quarter worth approximately $4,302,000. Finally, BlueCrest Capital Management Ltd acquired a new stake in shares of Natera during the second quarter worth approximately $11,695,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $414.30 on Friday. The stock has a market cap of $59.72 billion, a price-to-earnings ratio of -304.63 and a beta of 1.50. The business has a 50 day simple moving average of $377.06 and a 200 day simple moving average of $266.44. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm’s revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.74) earnings per share. On average, analysts predict that Natera, Inc. will post -1.14 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NTRA shares. Robert W. Baird set a $348.00 price objective on shares of Natera in a research note on Friday, August 7th. Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Royal Bank Of Canada lifted their target price on shares of Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. BTIG Research boosted their price target on shares of Natera from $320.00 to $430.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $394.31.

Insider Buying and Selling at Natera

In other news, CFO Michael Brophy sold 1,906 shares of the firm’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $425.55, for a total transaction of $811,098.30. Following the transaction, the chief financial officer owned 46,574 shares in the company, valued at approximately $19,819,565.70. This trade represents a 3.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 1,162 shares of Natera stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total transaction of $495,407.08. Following the completion of the sale, the insider directly owned 104,742 shares of the company’s stock, valued at approximately $44,655,704.28. The trade was a 1.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 51,654 shares of company stock valued at $17,973,105. 5.05% of the stock is currently owned by insiders.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

Natera Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.